.jetcityimage/iStock Content by means of Getty Images Morgan Stanley has chosen Eli Lilly (NYSE: LLY) as its best biopharma pick for 2025 and rated yet another nine labels in the area as over weight. The financial investment banking company claimed in a note that it remains to feel “diabesity is actually readied to come to be.